RxDoctor Payments Data

Soundarya Nagaraja Gowda, MD

Neurology · Roanoke, VANPI 1184821480

Payments from drug & device makers

$38,497in general payments, 2019–2025

Across 518 payments — averaging $74.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$23K
  • Livanova USA, Inc.$5K
  • UCB, Inc.$2K
  • AbbVie$1K
  • AstraZeneca$557
  • SK Life Science, Inc.$452
  • plus $5K from 51 others

What the payments were for

  • Consulting fees$17,13845%
  • Speaking & faculty fees$4,87513%
  • Travel & lodging$4,90913%
  • Food & beverage$11,16129%
  • Education$4151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neuropace, Inc.35$23,337
Livanova USA, Inc.13$5,455
UCB, Inc.108$2,219
AbbVie61$1,034
AstraZeneca(2 entities)17$557
SK Life Science, Inc.18$452
Novartis22$379
Biogen17$350
Lundbeck LLC17$345
EMD Serono, Inc.13$249
Lilly USA, LLC14$232
Genentech USA, Inc.10$225
Amneal Pharmaceuticals LLC13$223
Teva Pharmaceuticals USA, Inc.9$221
Johnson & Johnson5$221
TG Therapeutics, Inc.9$211
Eisai Inc.8$176
Amgen(2 entities)9$174
Harmony Biosciences LLC7$169
Jazz Pharmaceuticals Inc.6$158
Argenx US, Inc.5$147
Neurelis, Inc.10$146
Bristol Myers Squibb8$139
Grifols USA, LLC7$137
Axsome Therapeutics, Inc.6$116
Banner Life Sciences, LLC5$116
Pfizer5$107
Merz Pharmaceuticals, LLC4$96
Sanofi3$87
Alnylam Pharmaceuticals Inc.4$82
Sunovion Pharmaceuticals Inc.5$72
Neurocrine Biosciences, Inc.4$65
Sumitomo Pharma America, Inc.4$61
MDD US Operations, LLC3$60
Otsuka America Pharmaceutical, Inc.2$57
Mallinckrodt Hospital Products Inc.2$48
Octapharma USA, Inc.3$42
Corium, LLC2$41
Upsher-smith Laboratories LLC2$40
Ultragenyx Pharmaceutical Inc.2$38
Impel Pharmaceuticals Inc.2$37
Acadia Pharmaceuticals Inc2$36
Catalyst Pharmaceuticals, Inc.2$35
Kyowa Kirin, Inc.2$33
ANI Pharmaceuticals, Inc.1$33
Microtransponder, Inc.1$29
Biohaven Pharmaceuticals, Inc.1$29
Springworks Therapeutics, Inc.1$26
Biohaven Pharmaceutical Holding Company Ltd.1$22
CSL Behring1$20
Collegium Pharmaceutical, Inc.1$20
Cycle Pharmaceuticals Inc1$19
Abbott1$19
Takeda Pharmaceuticals U.S.A., Inc.1$17
Acorda Therapeutics, Inc1$14
Avion Pharmaceuticals1$14
Currax Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,497 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$101,327
Medicare patients
575
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Vigabatrin12$211,275
BriviactBrivaracetam29$58,868
XcopriCenobamate30$45,727
AptiomEslicarbazepine Acetate25$44,043
NayzilamMidazolam17$25,285
Keppra XrLevetiracetam11$24,925
DepakoteDivalproex Sodium15$21,052
Lacosamide113$16,246
QuliptaAtogepant21$14,996
FycompaPerampanel12$14,875
Aimovig AutoinjectorErenumab-Aooe17$13,849
LamictalLamotrigine13$13,257
TrileptalOxcarbazepine13$11,412
Lamotrigine OdtLamotrigine11$7,525
Levetiracetam212$7,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$2,219$84,15346 claims
SK Life Science, Inc.Xcopri$452$45,72730 claims
Sunovion Pharmaceuticals Inc.Aptiom$72$44,04325 claims
AbbVieQulipta$1,034$14,99621 claims
Eisai Inc.Fycompa$176$14,87512 claims
PfizerDilantin$107$3,35631 claims
Upsher-smith Laboratories LLCTopiramate$40$1,26072 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 neurology providers in Virginia.

Other neurology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →